Datasheet 2: Vitiligo - An Autoimmune Skin Disease and Its Immunomodulatory Therapeutic Intervention
December 2021
in “
OPAL (Open@LaTrobe) (La Trobe University)
”
TLDR New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
Vitiligo is a chronic autoimmune skin disorder characterized by the loss of functional melanocytes, with immune T cells, particularly CD8+ cytotoxic T cells and regulatory T cells, playing a significant role in its pathogenesis. Recent advancements in understanding the disease have led to the development of targeted therapies, such as Janus kinase (JAK) inhibitors, which have shown therapeutic significance. Additionally, mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have emerged as promising treatments due to their ability to regulate cytokine secretion and T-cell balance, offering anti-inflammatory effects. The document highlighted the progress in these therapies and emphasized the need for further research into vitiligo treatment.